Expression and significance of urinary microRNA in patients with chronic hepatitis B

Shang, Jiawei; Yan, Xin; Zhang, Hui; Su, Shi‐Bing

doi:10.1097/md.0000000000017143

Cited by 7 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, miRNAs associated with EVs can also be biomarkers for diseases other than cancer. miRNAs from EVs can be used for the detection of acute myocardial infarction 46 , 47 , chronic hepatitis B 48 , and their correlation with the presence of liver toxicity has been demonstrated in rat models 49 . Despite the obvious advantages of using EVs for disease detection, the small sample size and difficulty of separation are still the limiting factors for widespread use 50 , 51 .…”

Section: Components Of Urine Biopsymentioning

confidence: 99%

Urine biopsy technologies: Cancer and beyond

Chen¹,

Liao²,

Li³

et al. 2020

Theranostics

View full text Add to dashboard Cite

Since the discovery of circulating tumor cells in 1869, technological advances in the study of biomarkers from liquid biopsy have made it possible to diagnose disease in a less invasive way. Although blood-based liquid biopsy has been used extensively for the detection of solid tumors and immune diseases, the potential of urine-based liquid biopsy has not been fully explored. Advancements in technologies for the harvesting and analysis of biomarkers are providing new opportunities for the characterization of other disease types. Liquid biopsy markers such as exfoliated bladder cancer cells, cell-free DNA (cfDNA), and exosomes have the potential to change the nature of disease management and care, as they allow a cost-effective and convenient mode of patient monitoring throughout treatment. In this review, we addressed the advancement of research in the field of disease detection for the key liquid biopsy markers such as cancer cells, cfDNA, and exosomes, with an emphasis on urine-based liquid biopsy. First, we highlighted key technologies that were widely available and used extensively for clinical urine sample analysis. Next, we presented recent technological developments in cell and genetic research, with implications for the detection of other types of diseases, besides cancer. We then concluded with some discussions on these areas, emphasizing the role of microfluidics and artificial intelligence in advancing point-of-care applications. We believe that the benefits of urine biopsy provide diagnostic development potential, which will pave opportunities for new ways to guide treatment selections and facilitate precision disease therapies.

show abstract

Section: Components Of Urine Biopsymentioning

confidence: 99%

Urine biopsy technologies: Cancer and beyond

Chen¹,

Liao²,

Li³

et al. 2020

Theranostics

View full text Add to dashboard Cite

show abstract

“…[7] miRNAs play an important role in the progression of hepatitis B and HBV-related liver fibrosis and can be used as potential biomarkers. [8] Zhang et al [9] found that the serum levels of miR-122, miR-572, miR-575, miR-638, and miR-744 were dysregulated in patients with chronic hepatitis B or nonalcoholic steatohepatitis. The levels of these miRNAs may serve as biomarkers of liver damage caused by chronic hepatitis B and nonalcoholic steatohepatitis.…”

Section: Introductionmentioning

confidence: 99%

Expression of miR-223-3p in patients with hepatitis B virus liver fibrosis and its effect on hepatic stellate cells: An observational study

Zhang

2023

Medicine

View full text Add to dashboard Cite

To analyze miR-223-3p expression in patients with hepatitis B virus (HBV) live fibrosis and its effects on proliferation, activation, and apoptosis of human hepatic stellate cell line. One hundred patients with HBV-associated liver fibrosis were divided into S0 to 1, S2 to 3, and S4 groups according to Scheuer histological staging; healthy individuals during the same period were enrolled as healthy group. Relative expressions of miR-223-3p in healthy, S0 to 1, S2 to 3, and S4 groups were 0.56 ± 0.11, 1.08 ± 0.27, 2.16 ± 0.42, and 3.59 ± 1.06, respectively. Absorbance values of human hepatic stellate cell line cells at 24, 48, and 72 hours were higher in miR-223-3p-mimic group than in control group (CG) and NC-mimic group and were lower in miR-223-3p-inhibitor group than in CG and NC-inhibitor group (P < .05). mRNA miR-223-3p, α-smooth muscle actin, collagen 1A1, collagen 1A2, collagen 3A1, and transforming growth factor (TGF)-β1 levels were higher in miR-223-3p-mimic group than in CG and NC-mimic group and lower in miR-223-3p-inhibitor group than in CG and NC-inhibitor group (P < .05). Protein expressions of α-smooth muscle actin, transforming growth factor-β1, collagen I, collagen III, p-Smad3, p-Smad2, and B-cell lymphoma 2 were higher in miR-223-3p-mimic group than in CG and NC-mimic groups and lower in miR-223-3p-inhibitor group than in CG and NC-inhibitor group, whereas those of B-cell lymphoma 2-associated death promoter, B-cell lymphoma 2 associated X protein, cleaved caspase3, cleaved caspase9, poly ADP-ribose polymerase were lower in miR-223-3p-mimic group than in CG and NC-mimic group and higher in miR-223-3p-inhibitor group than in CG and NC-inhibitor group (P < .05). HBV liver fibrosis patients had elevated expression of miR-223-3p in plasma. Upregulation of miR-223-3p expression may be related to transforming growth factor-β1/Smad signaling pathway activation.

show abstract